3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
153
Lung Neoplasms
73
Pancreatic Neoplasms
44
Neoplasms
27
Neoplasm Metastasis
25
Head and Neck Neoplasms
23
Brain Neoplasms
21
Breast Neoplasms
18
Glioblastoma
15
Adenocarcinoma of Lung
15
Squamous Cell Carcinoma of Head and Neck
14
Gliosarcoma
14
Adenocarcinoma, Bronchiolo-Alveolar
11
Colorectal Neoplasms
10
Glioma
9
Carcinoma, Squamous Cell
8
Carcinoma, Hepatocellular
8
Adenocarcinoma
7
Rectal Neoplasms
6
Prostatic Neoplasms
6
Esophageal Neoplasms
6
Central Nervous System Neoplasms
6
Carcinoma, Renal Cell
6
Astrocytoma
6
Oligodendroglioma
5
Liver Neoplasms
5
Colonic Neoplasms
5
Carcinoma
5
Recurrence
4
Ovarian Neoplasms
4
Interventions
Docetaxel
5
Gemcitabine
3
Vinorelbine
2
Erlotinib Hydrochloride
2
Carboplatin
2
surufatinib
1
pemigatinib
1
nimotuzumab
1
lorlatinib
1
Pemetrexed
1
Paclitaxel
1
Gene Expression Profiling
1
Cisplatin
1
Cetuximab
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Non-Small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Clear all
NCT00349219
2016-01-15
TORCH
National Cancer Institute, Naples
Phase 3
Completed
760 enrolled
NCT00783471
2010-06-16
DOPERLO
Hellenic Cooperative Oncology Group
Phase 2
Terminated
51 enrolled